Clinical Trial Update: Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating daratumumab plus donor lymphocyte infusion in relapsed acute myeloid leukemia after stem cell transplantation was terminated, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Myelodysplasia-related Changes

Drugs mentioned

• Daratumumab (daratumumab)
• Donor Lymphocyte Infusion

Snippet

Sponsor: Sumithira Vasu | Conditions: Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-05-21